Lantheus Holdings Inc (LNTH) Unusual Options Activity Today

Checking LNTH unusual options activity helps you spot when traders are making outsized bets on Lantheus Holdings Inc before the broader market catches on. Lantheus Holdings Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor LNTH unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching LNTH unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking LNTH unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and LNTH unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Catalysts rarely arrive without a footprint, and LNTH unusual options activity is often where that footprint shows up first. Our scanner tracks Lantheus Holdings Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at LNTH unusual options volume on the call side or chasing put sweeps, Lantheus Holdings Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.